On Thursday, Shares of Mueller Water Products, Inc. (NYSE:MWA), dropped -3.60% to $9.36.
Mueller Water Products, declared that for its fiscal second quarter ended March 31, 2015, net sales were $290.3 million, contrast with $288.1 million in the preceding year. Operating income was $25.6 million contrast with $25.3 million in the preceding year, and adjusted operating income was $26.3 million contrast with $28.0 million in the preceding year. Income before income taxes raised 52.3 percent to $19.5 million contrast with $12.8 million in the preceding year. Net income per diluted share raised to $0.08 contrast with $0.06 in the preceding year, and adjusted net income per diluted share raised to $0.08 from $0.07. Adjusted EBITDA reduced to $40.7 million from $41.8 million in the preceding year.
Second Quarter Merged Results
Net sales for the 2015 second quarter raised $2.2 million, or 0.8 percent, to $290.3 million as contrast with $288.1 million for the 2014 second quarter, due to higher shipment volumes and improved pricing, partially offset by unfavorable Canadian currency exchange rates.
Adjusted operating income for the 2015 second quarter reduced $1.7 million to $26.3 million as contrast with $28.0 million for the 2014 second quarter.
Mueller Water Products, Inc. manufactures and markets products and services for the use in transmission, distribution, and measurement of water in the United States, Canada, and internationally. The company operates in two segments, Mueller Co. and Anvil.
Shares of Sunstone Hotel Investors Inc. (NYSE:SHO), declined -3.53% to $15.58, during its last trading session.
Sunstone Hotel Investors, will host a property tour and company presentation on Wednesday, June 24, 2015, in Boston at the Boston Park Plaza hotel. The event will comprise a presentation by the Company’s senior executives starting at 2:00 p.m., followed by a property tour and a reception.
Sunstone Hotel Investors, Inc. is a lodging real estate investment trust that, as of the date hereof, has interests in 30 hotels comprised of 14,306 rooms. Sunstone’s hotels are primarily in the upper upscale segment and are generally operated under nationally recognized brands, such as Marriott, Hilton, Hyatt, Fairmont and Sheraton.
At the end of Thursday’s trade, Shares of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), dwindled -3.50% to $8.81.
ZIOPHARM Oncology, declared the initiation of a Phase 1b/2 study of Ad-RTS-hIL-12 + veledimex following standard chemotherapy for the treatment of patients with locally advanced or metastatic breast cancer. The study will be conducted at the Memorial Sloan Kettering Cancer Center in New York led by principal investigator Heather L. McArthur, M.D., M.P.H., Assistant Attending Physician, Breast Medicine Service, Memorial Sloan Kettering Cancer Center. Ad-RTS-hIL-12 is a novel gene therapy candidate for the controlled expression of IL-12, an important protein for collapsing tumor stroma and stimulating an anti-cancer T cell immune response.
The study is designed to examine the safety, tolerability and efficacy of Ad-RTS-hIL-12 immunotherapy in women with locally advanced or metastatic breast cancer of all subtypes. Up to 40 subjects may be enrolled in the study, counting up to 20% (8 subjects) with HER2+ breast cancer. Subjects who are receiving first- or second-line standard therapy and have achieved a partial response or stable disease are eligible. Following entry into the trial, patients will go on a treatment holiday from chemotherapy and enter an immunotherapy phase of treatment. A single cycle of Ad-RTS-hIL-12, together with the oral activator ligand veledimex, will be given during the immunotherapy phase, with the aim of maintaining or improving pre-study response. Continuation of HER2-targeted antibody therapy is permitted during this immunotherapy phase for women with HER2+ disease. The primary study objective is to evaluate the safety and tolerability of Ad-RTS-hIL-12 immunotherapy. Secondary objectives comprise overall response rate, disease control rate and impact of treatment on tumor and serum immune biomarkers.
ZIOPHARM Oncology, Inc., a biotechnology company, employs gene expression, control, and cell technologies to deliver cell-based therapies for the treatment of cancer. Its synthetic immuno-oncology programs, in partnership with Intrexon Corporation and the MD Anderson Cancer Center, comprise chimeric antigen receptor T cell (CAR-T) and other adoptive cell based approaches that use both non-viral and viral gene transfer methods for broad scalability.
Finally, Ericsson (NASDAQ:ERIC), ended its last trade with -3.45% loss, and closed at $10.92, hitting its lowest level.
Ericsson, declared that Gartner, Inc., the world`s leading information technology research and advisory company, continues to position Ericsson as an LTE industry leader within the “Leaders” quadrant of its 2015 Magic Quadrant for LTE Infrastructure report, now for the sixth year running. Ericsson was positioned highest for ability to execute in this year`s report, published April 20, 2015. The report examines vendors of end-to-end (radio and core) LTE network infrastructure and positions them based on their ability to execute and completeness of vision in the LTE market.
Ericsson attributes ability to execute in part to strong financial metrics and a broad portfolio contributes to completeness of vision, counting such sought-after advanced technologies as LTE-Advanced (LTE-A) with combined-mode FDD (frequency division duplex) and TDD (Time Division Duplex), Network Function Virtualization (NFV), unified administration and the modular Ericsson Radio System with integrated transport. Ericsson is also active with ecosystem partners for other verticals, such as public safety, machine-type communications (MTC/M2M), the Internet of Things (IoT), and connected cars.
Ericsson provides communications technology and services worldwide. The company’s Networks segment delivers products and solutions for mobile access, Internet protocol (IP) and transmission networks, core networks, and cloud.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
